title: Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.
abstract: BACKGROUND
  Low bone mass and high bone turnover have been reported in HIV-infected individuals, both as a consequence of HIV infection itself, as well as from treatment with highly active antiretroviral therapy (HAART). The purpose of this study is to evaluate the impact of HAART on bone mineral density and bone turnover in HIV-1 infected Chinese patients.
  
  
  METHODS
  Forty HIV-1 infected patients were enrolled in this study; all patients were followed through 48 weeks, and 17 patients completed 96 weeks. Bone mineral density (BMD), procollagen type 1 N-terminal propeptide (P1NP), collagen type 1 cross-linked C-telopeptide (β-CTX), parathyroid hormone (PTH), and 25-OH vitamin D levels were measured at baseline, 48 and 96 weeks. Baseline measurements were compared with an age-, gender-, and BMI-matched healthy control population.
  
  
  RESULTS
  At baseline, raw BMD in the lumbar spine of HIV-1 infected patients was significantly lower than that of healthy controls (1.138 ± 0.112 g/cm2 vs. 1.195 ± 0.139 g/cm2, p = 0.047). During the first 48 weeks after initiating HAART, BMD of lumbar spine, femoral neck, and total hip decreased significantly in HIV-1 infected patients, with annual percent decline ranging from 1.78-3.28%. However, from week 48 to 96, BMD remained stable. Baseline levels of β-CTX (0.31 ± 0.16 ng/mL vs. 0.42 ± 0.19 ng/mL, p = 0.008) and P1NP (32.96 ± 14.00 ng/mL vs. 55.82 ± 26.87 ng/mL, p = 0.05) were lower in HIV-infected patients compared with controls, respectively. Both β-CTX and P1NP levels increased after onset of HAART until week 48, and remained elevated during the next 48 weeks. 25-OH vitamin D in HIV-infected patients was lower at baseline compared to healthy controls, but this difference was not statistically significant. PTH, however, was higher in HIV patients at baseline, and showed a significant increase throughout the study.
  
  
  CONCLUSIONS
  Chinese adults with HIV-1 infection have low bone turnover prior to HAART as well as lower raw BMD of the lumbar spine compared with healthy controls, with further bone loss occurring following the initiation of HAART. The long-term clinical implications of these findings remain unclear at this time.
authors.forename: Lixia
authors.initials: L
authors.lastname: Zhang
authors.forename: Yuanbo
authors.initials: Y
authors.lastname: Su
authors.forename: Evelyn
authors.initials: E
authors.lastname: Hsieh
authors.forename: Weibo
authors.initials: W
authors.lastname: Xia
authors.forename: Jing
authors.initials: J
authors.lastname: Xie
authors.forename: Yang
authors.initials: Y
authors.lastname: Han
authors.forename: Ying
authors.initials: Y
authors.lastname: Cao
authors.forename: Yanling
authors.initials: Y
authors.lastname: Li
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Song
authors.forename: Ting
authors.initials: T
authors.lastname: Zhu
authors.forename: Taisheng
authors.initials: T
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Yu
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D044466:Asian People / Q000208:ethnology; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D055815:Young Adult
references.citation: Bone. 1995 Feb;16(2):185-91
references.pmid: 7756046
references.citation: Zhonghua Nei Ke Za Zhi. 2010 Aug;49(8):649-52
references.pmid: 20979781
references.citation: PLoS One. 2011 Feb 16;6(2):e17217
references.pmid: 21359191
references.citation: Am J Public Health. 1988 Nov;78(11):1482-3
references.pmid: 3177728
references.citation: J Clin Endocrinol Metab. 1999 Jan;84(1):145-50
references.pmid: 9920075
references.citation: J Bone Miner Res. 2009 Dec;24(12):1953-9
references.pmid: 20001598
references.citation: BMC Infect Dis. 2012 Feb 14;12:38
references.pmid: 22333484
references.citation: AIDS. 2013 Feb 20;27(4):573-8
references.pmid: 23095316
references.citation: J Infect Dis. 2011 Jun 15;203(12):1791-801
references.pmid: 21606537
references.citation: Eur J Clin Pharmacol. 2006 Oct;62(10):781-92
references.pmid: 16912870
references.citation: J Clin Endocrinol Metab. 2010 Feb;95(2):620-9
references.pmid: 19965927
references.citation: J Clin Endocrinol Metab. 2013 Apr;98(4):1659-66
references.pmid: 23436922
references.citation: J Clin Endocrinol Metab. 2006 Aug;91(8):2938-45
references.pmid: 16735489
references.citation: PLoS One. 2011;6(10):e26739
references.pmid: 22066007
references.citation: J Infect. 2003 May;46(4):221-7
references.pmid: 12799147
references.citation: J Clin Endocrinol Metab. 2008 Sep;93(9):3499-504
references.pmid: 18593764
references.citation: J Acquir Immune Defic Syndr. 2011 Apr;56(4):320-4
references.pmid: 21350365
references.citation: Antivir Ther. 2011;16(4):555-63
references.pmid: 21685543
references.citation: PLoS One. 2012;7(2):e31726
references.pmid: 22359621
references.citation: AIDS. 2006 Nov 14;20(17):2165-74
references.pmid: 17086056
references.citation: Am J Epidemiol. 1991 Apr 15;133(8):801-9
references.pmid: 2021147
references.citation: Bone. 2006 Jun;38(6):893-7
references.pmid: 16377270
references.citation: AIDS Res Hum Retroviruses. 2008 Nov;24(11):1375-82
references.pmid: 18928396
references.citation: AIDS Res Ther. 2010 Nov 23;7:40
references.pmid: 21092280
references.citation: J Infect Dis. 1994 Apr;169(4):889-93
references.pmid: 7907645
references.citation: Climacteric. 2008 Feb;11(1):44-54
references.pmid: 18202964
references.citation: Clin Infect Dis. 2011 Feb 1;52(3):396-405
references.pmid: 21217186
references.citation: Antivir Ther. 2011;16(7):1063-72
references.pmid: 22024522
references.citation: J Clin Densitom. 2011 Jan-Mar;14(1):58-62
references.pmid: 21130671
references.citation: Ethn Dis. 2004 Spring;14(2):280-4
references.pmid: 15132215
references.citation: J Infect Dis. 2009 Dec 1;200(11):1746-54
references.pmid: 19874178
references.citation: HIV Med. 2011 Mar;12(3):157-65
references.pmid: 20722752
references.citation: Clin Pharmacokinet. 2003;42(6):599-605
references.pmid: 12793844
references.citation: HIV Clin Trials. 2003 Sep-Oct;4(5):337-46
references.pmid: 14583850
references.citation: Br J Nutr. 2010 Jun;103(12):1706-10
references.pmid: 20102676
references.citation: AIDS. 2009 Apr 27;23(7):817-24
references.pmid: 19363330
references.citation: AIDS. 2012 Jan 28;26(3):253-62
references.pmid: 22112601
references.citation: Bone. 2012 May;50(5):1141-7
references.pmid: 22348982
references.citation: J Bone Miner Res. 1999 Sep;14(9):1614-21
references.pmid: 10469291
references.citation: J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):554-61
references.pmid: 19512937
references.citation: HIV Clin Trials. 2007 May-Jun;8(3):164-72
references.pmid: 17621463
references.citation: J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):197-204
references.pmid: 21471818
references.citation: AIDS Res Hum Retroviruses. 2012 Mar;28(3):235-41
references.pmid: 21644847
references.citation: Clin Infect Dis. 2010 Oct 15;51(8):963-72
references.pmid: 20828304